Glide Pharma, a Abingdon, UK-based pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, has completed a £2.7m (approximately $4.3m) investment round.
The round was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs.
The company has now completed four successful investment rounds, securing funding totalling approximately £10m.
Glide will use the new funds to progress its Glide octreotide programme into clinical development and to continue scale-up of its commercial manufacturing process.
The investment follows the recent successful clinical proof-of-concept of its proprietary solid dose injector, the Glide SDI(R), which avoids the bruising and bleeding associated with needle and syringe delivery.